Eli Lilly and Dermira

Selected news for the company - Eli Lilly, and the company - Dermira. We have 73 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
8/16/2021 Lilly's drug boosts skin clearance in Phase III atopic dermatitis trials ... trials In the trials, lebrikizumab offered a reduction in itch and interference of itch on sleep and quality of life. Eli Lilly has reported that its drug, lebrikizumab, provided substantial skin clearance in more than ... inflammation and mediating its effects on tissue. In October 2019, Dermira commenced a Phase III programme comprising two identical trials of lebrikizumab for the treatment of moderate-to-severe AD. The ongoing 52-week randomised ...
4/14/2021 A year after buyout, Lilly to shutter Dermira's Menlo Park facility and shed 163 jobs FiercePharma Eli Lilly took a sizable leap into the dermatology market last year with its $1.1 billion acquisition of Dermira, picking up Qbrexza, the medicated cloth for excessive sweating, and a potential rival to Regeneron and Sanofi‚Aos atopic dermatitis blockbuster Dupixent.Now, about a year later, Lilly is selling Qbrexza and plans to shutter Dermira‚Aos Menlo Park facility, shedding 163 jobs along the way, the San Francisco Business Times ...
4/13/2021 Lilly Closes Dermira's Menlo Park Facility Lilly Closes Dermira‚Aos Menlo Park Facility, Cutting 163 Jobs in the ProcessEli Lilly and Company is set to cut 163 jobs as it closes its Dermira facility in Menlo Park and sells off the latter company‚Aos sweat drug Qbrexza, which is being snatched up by Journey Medical.Lilly acquired medical dermatology focused Dermira back in 2020 for $1.1 billion, giving the company rights to its excessive underarm ...
1/14/2021 ... en/Follica announced the appointment of two veteran biotech executives to its Board of Directors. Tom Wiggans, former CEO of Dermira, joins as Executive Chairman, and Michael Davin, former CEO of Cynosure, joins as an ... monoclonal antibody for atopic dermatitis. Mr. Wiggans guided Dermira through Eli Lilly‚Aos acquisition of the company for approximately $1.1 billion in January of 2020.Michael Davin joins as an independent member of the Board ...
1/14/2021 ... en/Follica announced the appointment of two veteran biotech executives to its Board of Directors. Tom Wiggans, former CEO of Dermira, joins as Executive Chairman, and Michael Davin, former CEO of Cynosure, joins as an ... monoclonal antibody for atopic dermatitis. Mr. Wiggans guided Dermira through Eli Lilly‚Aos acquisition of the company for approximately $1.1 billion in January of 2020.Michael Davin joins as an independent member of the Board ...
8/20/2020 Top 5 pharmaceutical M&A deals this year Becker's Hospital Review ... Eli Lilly's acquisition of Dermira — $1.1 billion Takeda's divestiture of select drugs to Hypera Pharma — $825 million More articles on pharmacy ...
7/24/2020 Pharma deal values plummet 56% as COVID-19 disrupts resources: report FiercePharma ... Eli Lilly paid $1.1 billion for Dermira in January, but then dealmaking in Big Pharma all but shut down. In fact, there were no major deals in the sector after that until March, when Takeda shed 18 over-the-counter drugs to Hypera for $825 million. Biotech saw one mega deal in early March—Gilead’s $4.9 billion purchase of cancer drugmaker Forty Seven. Novo Nordisk picked up Corvidia for $2.1 ...
6/15/2020 Healthcare & Life Sciences Update - June 2020 ... Dermira Inc. (NasdaqGS:DERM) by Eli Lilly and Company (NYSE:LLY), InTouch Technologies Inc. by Teladoc Health (NYSE:TDOC) and Decision Resources Inc. by Clarivate Analytics Plc. (NYSE:CCC). 1 Public Company Performance Stock prices increased for many healthcare and life sciences (HCLS) companies during the past three months. In fact, the Harris Williams HCLS Composite Index increased 6.9%, while the S&P increased 4.9%. Notable sector increases include contract ...
6/12/2020 Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD) PR Newswire INDIANAPOLIS , June 12, Eli Lilly and Company (NYSE: LLY ) announced today that it will present new data from Taltz ® (ixekizumab), Olumiant ® (baricitinib), mirikizumab and lebrikizumab at the virtual American Academy of Dermatology (AAD) meeting. The ... would be expanding its dermatology portfolio through the acquisition of Dermira, a biopharmaceutical company dedicated to developing new medicines for chronic skin conditions. This acquisition reinforces Lilly's commitment to dermatology and creating new medicines for ...
6/12/2020 Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life PR Newswire Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company) INDIANAPOLIS , June 12, Eli Lilly and Company (NYSE: LLY ) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the Phase 2b clinical trial of lebrikizumab in patients with moderate-to-severe atopic dermatitis. Data from this study suggests that treatment with lebrikizumab provided ...
6/12/2020 Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD) | Benzinga Benzinga INDIANAPOLIS , June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it will present new data from Taltz ® (ixekizumab), Olumiant ® (baricitinib), mirikizumab and lebrikizumab at the virtual American Academy of Dermatology (AAD ... would be expanding its dermatology portfolio through the acquisition of Dermira, a biopharmaceutical company dedicated to developing new medicines for chronic skin conditions. This acquisition reinforces Lilly's commitment to dermatology and creating new medicines for ...
6/12/2020 Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD) - GuruFocus.com ... and develop medicines for patients living with dermatological conditions PR Newswire INDIANAPOLIS, June 12, 2020 INDIANAPOLIS , June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from ... would be expanding its dermatology portfolio through the acquisition of Dermira, a biopharmaceutical company dedicated to developing new medicines for chronic skin conditions. This acquisition reinforces Lilly's commitment to dermatology and creating new medicines for ...
6/12/2020 Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD) BioSpace INDIANAPOLIS , June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz ® (ixekizumab), Olumiant ® (baricitinib), mirikizumab and lebrikizumab at the virtual American Academy of Dermatology (AAD ... would be expanding its dermatology portfolio through the acquisition of Dermira, a biopharmaceutical company dedicated to developing new medicines for chronic skin conditions. This acquisition reinforces Lilly's commitment to dermatology and creating new medicines for ...
6/12/2020 Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life | BioSpace BioSpace Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life Published: Jun 12, 2020 INDIANAPOLIS , June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the Phase 2b clinical trial of lebrikizumab in patients with moderate-to-severe ...
6/12/2020 Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life Order a Press Kit News Releases Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life Data presented at virtual American Academy of Dermatology 2020 Annual Meeting INDIANAPOLIS , June 12, 2020 / PRNewswire / -- Eli Lilly and Company (NYSE: LLY) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from ...
6/12/2020 Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life By Eli Lilly and Company;American Academy of Dermatology 2020 Annual Meeting;Dermira, Inc.; Jun 12, 2020 Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) By Eli Lilly and Company;American Diabetes Association's 80th Scientific Sessions; By Eli Lilly and Company;American ...
6/12/2020 Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD) Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD) By Eli Lilly and Company Jun 12, 2020 Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsfoto ... would be expanding its dermatology portfolio through the acquisition of Dermira, a biopharmaceutical company dedicated to developing new medicines for chronic skin conditions. This acquisition reinforces Lilly's commitment to dermatology and creating new medicines for ...
6/12/2020 Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life - GuruFocus.com Data presented at virtual American Academy of Dermatology 2020 Annual Meeting PR Newswire INDIANAPOLIS, June 12, 2020 INDIANAPOLIS , June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the Phase 2b clinical trial of lebrikizumab in patients with moderate-to-severe atopic dermatitis. Data from this study suggests that treatment with lebrikizumab provided rapid ...
6/12/2020 Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life Data presented at virtual American Academy of Dermatology 2020 Annual Meeting Print this page INDIANAPOLIS, June 12, and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the Phase 2b clinical trial of lebrikizumab in patients with moderate-to-severe atopic dermatitis. Data from this study suggests that treatment with lebrikizumab provided rapid and clinically meaningful improvements in itch, sleep and overall measures of quality of life. Emma Guttman-Yassky, M.D., Ph.D., a leading investigator ...
4/23/2020 Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance PR Newswire INDIANAPOLIS Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2020. $ in millions, except per share data First Quarter % 2020 2019 Change Revenue $ 5,859.8 $ 5,092.2 15% Net Income – Reported ... medicines for autoimmune diseases. The company completed the acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, which is being evaluated in a Phase 3 clinical development program for ...
4/23/2020 Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance | Markets Insider Business Insider INDIANAPOLIS , April 23, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2020. $ in millions, except per share data First Quarter % 2020 2019 Change Revenue $ 5,859.8 $ 5,092.2 ... medicines for autoimmune diseases. The company completed the acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, which is being evaluated in a Phase 3 clinical development program for ...
4/23/2020 Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance | BioSpace BioSpace ... Dermira acquisition. 2020 EPS guidance adjusted to be in the range of $6.20 to $6.40 on a reported basis and $6.70 to $6.90 on a non-GAAP basis. INDIANAPOLIS , April 23, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2020. Certain financial information for 2020 and 2019 is presented on both a reported and a non-GAAP basis. Some numbers in ...
4/2/2020 Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis - April 2, 2020 - Zacks.com Zacks ... industry, comprising some of the biggest drugmakers in the world, has declined 11% this year so far. Amid this crisis, Eli Lilly’s ( LLY - Free Report ) stock stands tall. Last month, Lilly announced that it is ... through business development deals. This year, Lilly bought dermatology company Dermira for approximately $1.1 billion. The deal added Dermira’s promising interleukin inhibitor for atopic dermatitis/eczema, lebrikizumab, thereby expanding Lilly’s immunology pipeline. Lilly has its ...
4/2/2020 Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis - April 2, 2020 - Zacks.com Zacks ... industry, comprising some of the biggest drugmakers in the world, has declined 11% this year so far. Amid this crisis, Eli Lilly’s ( LLY - Free Report ) stock stands tall. Last month, Lilly announced that it is ... through business development deals. This year, Lilly bought dermatology company Dermira for approximately $1.1 billion. The deal added Dermira’s promising interleukin inhibitor for atopic dermatitis/eczema, lebrikizumab, thereby expanding Lilly’s immunology pipeline. Lilly has its ...
4/1/2020 Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy - April 1, 2020 - Zacks.com Zacks Eli Lilly ( LLY - Free Report ) stock closed the first quarter above where it started, which was no easy task since the Dow just ended its worst quarter since 1987 and the S&P 500 suffered ... its roughly $1.1 billion acquisition of chronic skin conditions specialist Dermira. Lilly’s broader portfolio of medicines includes treatments that focus on everything from diabetes to cancer and cardiovascular health. Investors should note that the company ...